# Hossein Borghaei

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hossein-borghaei/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,069 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 65 |
| i10-index | 180 |
| Last Known Institution | Fox Chase Cancer Center |
| OpenAlex ID | https://openalex.org/A5012061864 |
| ORCID iD | https://orcid.org/0000-0002-2577-4454 |
| Works | 515 |

## Researcher papers

Showing 12 of 13.

- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation](https://scholariq.org/papers/sotorasib-for-lung-cancers-with-i-kras-i-p-g12c-mutation/)
- [Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/genomic-features-of-response-to-combination-immunotherapy-in-patients-with/)
- [Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study](https://scholariq.org/papers/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell/)
- [Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-4-2016/)
- [Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057/)
- [Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial](https://scholariq.org/papers/alectinib-in-alk-positive-crizotinib-resistant-non-small-cell-lung-cancer-a/)
- [Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer](https://scholariq.org/papers/tarlatamab-for-patients-with-previously-treated-small-cell-lung-cancer/)
- [Non–Small Cell Lung Cancer, Version 6.2015](https://scholariq.org/papers/non-small-cell-lung-cancer-version-6-2015/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Fox Chase Cancer Center](https://scholariq.org/institutions/fox-chase-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.